Fibroblastic reticular cells (FRC) of lymphoid T zones actively promote T cell trafficking, homeostasis and expansion, but can also attenuate excessive T cell responses via inducible nitric oxide and constitutive prostanoid release. It has remained unclear under which conditions these FRC-derived mediators can dampen T cell responses and whether this occurs in vivo. Here we confirm that murine lymph node FRC produce prostaglandin E 2 (PGE 2 ) in a cyclooxygenase-2 (COX2)-dependent and inflammation-independent fashion. We show that this COX2/PGE 2 pathway is active during both strong and weak T cell responses, in contrast to nitric oxide which only comes into play during strong T cell responses. In chronic infections in vivo, PGE 2 -receptor signaling in virus-specific CD8 T cells was shown by others to suppress T cell survival and function. Using CCL19cre x COX2 flox/flox mice we now identify CCL19cre + FRC as the critical source of this COX2-dependent suppressive factor, suggesting PGE 2 -expressing FRC within lymphoid tissues are an interesting therapeutic target to improve T cell mediated pathogen control during chronic infection.
Introduction
Lymph nodes (LN) are secondary lymphoid organs (SLO) specialized in filtering lymph fluid and initiating T and B cell responses to foreign antigens. Typically, antigen-specific T cells are selected to expand and differentiate into effector cells by dendritic cells (DC) that present processed antigen in the context of MHC and costimulatory signals. However, T cells may also be tolerized if self-antigens are presented in a non-immunogenic context, typically by immature DC. All of these processes take place within the T cell rich compartment of SLO which are organized by FRC that are the most prevalent non-hematopoietic cell type in this zone and play active immune regulatory roles (1, 2) .
Initially, FRC have mainly been described to enhance adaptive immunity in several ways.
FRC constitutively produce the chemokines CCL19 and CCL21 responsible for attracting and retaining dendritic cells and naïve T cells in that compartment and thereby facilitating their physical interaction (3, 4) . These encounters are further enhanced by the dense reticular network formed by FRC, allowing DC adhesion and physical guidance for migrating T cells during their continuous search for antigen (5, 6) . FRC play yet another important role in promoting adaptive immunity by producing the T cell survival factor interleukin-7 (IL-7) (3).
More recently, evidence has accumulated for negative regulatory roles of FRC in T cell responses (1, 2) . FRC were shown to express self-antigens in the context of MHCI (7) or to acquire antigens and MHCII molecules from neighboring DC (8) with evidence suggesting induction of peripheral T cell tolerance. However, FRC can also inhibit T cell responses as bystander cells, presumably without need of antigen presentation. Ex vivo FRC were demonstrated to express inducible nitric oxide synthase (iNOS) upon detection of IFNg and TNFa derived from T cells shortly after priming, leading to a nitric oxide (NO)-dependent attenuation of T cell proliferation (9-11). This mechanism was shown to be limited to the early phase of T cell priming, leading to a reduced expansion of T cells that were nevertheless functional. While strong in vivo evidence for a critical role of iNOS or self-antigen in FRC dampening T cell responses is still scarce, these findings suggest that FRC may protect tissues against damage caused by very strong and potentially pathogenic T cell responses.
During our initial studies with FRC lines, we observed that part of the inhibitory activity was dependent on cyclooxygenase (COX) enzymes, as it could be blocked by the pharmacological inhibitor indomethacin. Interestingly, COX2 expression by our LN FRC line was found to be constitutive, in contrast to the cytokine-induced iNOS expression (11) . This initial finding suggested that FRC may have more than one pathway capable of dampening T cell responses, but the relative roles of COX versus iNOS in FRC remained unclear, as did the precise context, mechanism and in vivo role of COX2 specifically in FRC.
Results

Lymph node FRC dampen CD8+ and CD4+ T cell responses in vitro via constitutive production of COX2-dependent prostanoids
We have previously described the COX-dependent attenuation of T cell expansion in a coculture system where T cells were activated by antigen-loaded DCs in presence of FRC (11) .
To exclude a role for DC as source of COX-dependent prostanoids and to study more specifically the role of COX2 in FRC, we activated naïve murine T cells using aCD3/28coated beads in presence or absence of the FRC line called pLN2. In presence of FRC CD8+ and CD4+ T cell proliferation was strongly attenuated, as assessed by analyzing the percentage and absolute numbers of proliferating T cells, and this inhibitory effect could be reversed to a similar extent by adding either the iNOS inhibitor 1400W or the COX1/2-inhibitor indomethacin (Fig. 1A) . The inhibitors enhanced the CD4+ and CD8+ T cell expansion around 3-5fold with the response reaching 35-70% of the T cell response observed in absence of FRC. While FRC typically attenuated 85-95% of the T cell response in this coculture assay, these pharmacological inhibitors reduced this attenuating effect by a factor of 2-3 fold, allowing many T cells to undergo several rounds of cell division and to express more of the activation markers CD44 and CD25 (Fig. 1A, B , S1A). Interestingly, among the proliferating T cells there were only small differences observed regarding CD44 and CD25 expression in the various settings ( Fig. 1B, S1A ) suggesting FRC-expressed iNOS and COX2 reduce the number of T cells getting primed, with less effects on T cells once they have successfully entered cell cycle.
FRC express the prostanoid PGE 2 which acts on EP2/4 receptors on T cells to inhibit their expansion
To investigate under which conditions the iNOS and COX pathways become active in lymph node fibroblasts, we initially analyzed the transcript levels of these enzymes in pLN2 cells as well as ex vivo LN FRC. Consistent with previous data (9-11) the gene coding for iNOS, nos2, was not detectable in naive pLN2 but strongly induced 7h after stimulation with IFNg/TNFa or LPS while ptgs2 (COX2) was highly expressed in unstimulated pLN2 without major changes upon cytokine stimulation ( Supplementary Fig. 1B) . Similarly, ptgs1 (COX1) transcripts were constitutively expressed in pLN2 but at 10-fold lower levels than ptgs2 suggesting COX2 is the isoform preferentially expressed in pLN2 cells and responsible for the attenuating effect observed on T cell expansion. To test whether this holds true in vivo, peripheral LN (pLN) and spleen from adult wt mice were passed through a mesh to enrich either for lymphocytes or 'non-soluble' stromal cells (4) . Transcripts for both COX isoforms were enriched 5-50 fold in the stromal cell fraction of pLN with less marked differences observed for the splenic fractions ( Supplementary Fig.1C ). To identify the stromal cell types expressing ptgs1/2 in naïve pLN, various cell populations from naïve pLN were purified and analyzed. While ptgs1 transcripts were found at similar levels in FRC and endothelial cells, ptgs2 transcripts were expressed at 100-fold higher levels in FRC relative to endothelial, myeloid or lymphoid cells (Fig.1C) .
Notably, transcript levels of ptgs2 were approximately 1000-fold higher in FRC than of ptgs1 indicating COX2 is the principle isoform expressed by naïve pLN FRC.
COX enzymes are critical enzymes for the production of lipid intermediates that get further metabolized to produce the different effector molecules of the prostaglandin and thromboxane family. Previous studies have shown that high COX2 expression often correlates with high levels of PGE 2 , with this prostanoid being known to inhibit T cell activation and proliferation in various settings (12) (13) (14) (15) (16) . As PGE 2 production depends on prostaglandin E synthases, we assessed the transcript levels of all three isoforms (ptges1-3). Both in naïve pLN and spleen all three isoforms were expressed in the stromal cell fraction with ptges1 and ptges3 being preferentially expressed in that fraction ( Supplementary Fig. 1D ). Consistent with a constitutive activity of this pathway in FRC, overnight culture of the pLN2 FRC cell line led to the accumulation of 10-15ng/ml PGE 2 in the supernatant which was abolished in presence of indomethacin ( Fig. 1D ). In addition, pLN FRC isolated and sorted from d5 OVA/Montanide immunized mice produced high concentrations of PGE 2 as well, about 10-fold more than macrophages isolated from the same LN (Fig. 1E ). These findings point to FRC being a rich constitutive PGE 2 source in naïve and activated pLN.
To assess the direct effect of PGE 2 on T cell activation and proliferation, naïve T cells were stimulated in the presence of increasing PGE 2 concentrations. In line with previous data (12) we found that the proliferation of CD8+ and to a greater extent CD4+ T cells was impaired in presence of PGE 2 ( Fig. 2A ) at concentrations similar to those produced by FRC. Dampened T cell proliferation was accompanied by reduced CD25 upregulation and reduced CD62L loss on total and proliferating T cells whereas CD44 levels were less altered ( Fig. 2B and Supplementary Fig. 2A, B ). To determine if PGE 2 is the attenuating factor produced by COX2expressing FRC we used antagonists for the two high affinity receptors for PGE 2 , EP2 and EP4, expressed by T cells (12, 14) . Indeed, CD4+ and CD8+ T cell proliferation was rescued when the EP4 inhibitor was added to the co-culture system, to an extent comparable to indomethacin itself ( Fig. 2C, D) . The effect of the EP2 inhibitor was less pronounced. In summary, these in vitro results support the notion that PGE 2 may be the major COX2 dependent prostanoid released by pLN FRC dampening T cell responses by signaling via the EP4-receptor on naïve T cells.
FRC-derived prostanoids can suppress both weak and strong T cell responses in vitro while FRC-derived NO mainly dampens strong T cell responses
Given that we have identified COX2/PGE 2 as the second pathway in FRC able to attenuate T cell responses, besides iNOS/NO, we wished to address why FRC have two distinct mechanisms to dampen T cell expansion. Based on the constitutive versus inflammation-induced expression of COX2 and iNOS, respectively, we hypothesized that iNOS-mediated T cell inhibition may only act during strong T cell responses, when a certain threshold level of inflammation is reached, whereas COX2 mediated T cell inhibition may act on strong and weak T cell responses and thus affect also low affinity and possibly autoreactive T cells. To test this hypothesis, we used various model systems to mimic strong versus weak T cell responses. First, we analyzed OT-1 T cell proliferation upon stimulation with BM-DCs loaded with different concentrations of ovalbumin (OVA) peptide, either of high (N4) or low (V4) affinity for the OT-1 T cell receptor (TCR) (21) . Although at least 100 times more V4 than N4 peptide was needed to induce T cell proliferation and CD44 upregulation in vitro, we did not find a suitable condition leading to weak T cell expansion ( Supplementary Fig. 3A ), in line with previous evidence (21) . When FRC were added in a setting of strong TCR stimulation, due to a high N4 concentration, or in settings of weaker TCR stimulation, such as low N4 or high V4 concentration, always a robust inhibition of T cell proliferation was observed ( Supplementary Fig. 3B ). Relatively high NO levels were found in the supernatant of all three conditions indicating that there was sufficient inflammation to induce iNOS expression ( Supplementary Fig. 3C ). As BMDC may contribute NO or Cox-dependent prostanoids in this assay ( Fig.S3 C) (11, 16) , we decided to investigate different strengths of T cell activation in the absence of DC, by using beads loaded with different concentrations of aCD3/28 antibodies. In this experimental system, increasing aCD3/28 concentrations were reflected by a more gradual increase in the expansion of CD4+ and CD8+ T cells ( Fig.3 A and B ). Adding pLN2 cells in lower or higher numbers attenuated the T cell expansion more extensively with weaker than stronger T cell stimuli, especially for CD8+ T cells, with this effect being also visible at the level of CD25 and CD44 upregulation ( Fig.3 A and B) . NO levels increased with increasing FRC number and TCR strength, but showing an inverse correlation with T cell inhibition by FRC ( Fig. 3A, C) . In previous work, early IFNg by T cells was shown to be responsible for iNOS/NO expression in FRC, which then acts in a negative feedback loop to reduce the number of T cells recruited into the response (9-11). When cocultures of FRC and T cells were analyzed already on d1 of co-culture a clear correlation was observed between the strength of TCR activation and the percentage of activated and IFNg + CD8+ T cells induced, as well as with the NO level in the culture supernatant ( Supplementary Fig.4 A-C).
Flow cytometric and histological analysis confirmed the correlation between iNOS protein expression in FRC with TCR signal strength and IFNg release ( Fig.4 A and B ). Indeed, pharmacological inhibition of iNOS activity with 1400W abolished the suppressive effect by FRCs in the setting of a strong but not weak T cell stimulation ( Fig. 4C ). These findings support our hypothesis that only strong T cell stimulation leads to IFNg secretion by T cells sufficient to induce NO in FRC which then limits the number of T cells recruited into the response.
Previous evidence for a role of iNOS in dampening T cell expansion in vivo have been collected for strong immune responses only (9-11). To test whether this process is absent for weaker immune responses, wt and iNOS -/mice having received ovalbumin-reactive CD8+
(OT-1) T cells were immunized s.c. with different doses of OVA/Montanide to mimic different TCR stimulation levels ( Fig. 4D ). While on average there was an increased OT-1 T cell response in iNOS-deficient mice that received high antigen doses compared to wt control mice, this difference was not observed with low or intermediate antigen doses. Similar to previous studies (10, 11), no differences were observed in the expression of activation marker or in the killing capacity of OT-1 T cells isolated from either wt or iNOS-deficient mice (Supplementary Fig.4 D and E).
Having shown that iNOS expression in FRC depends on the level of IFNg secreted by the neighboring T cells, we hypothesized that the suppressive effect mediated by iNOS may be more pronounced in a secondary response by memory T cells able to sense less antigen and produce IFNg more quickly (22, 23) . To this end, wt and iNOS 
FRC-specific deletion of COX2 does not affect T cell homeostasis or clonal expansion in vivo
As Flow cytometric analysis revealed that 90% of pLN FRC were EYFP+, whereas less than 15% of endothelial cells and CD31-pdpn-cells were EYFP+, with no detectable Cre activity observed within hematopoietic cells ( Supplementary Fig. 5A and data not shown). Among the two major FRC subsets, an average of 96% of T zone FRC and 76% of Medullary FRC exhibited Cre activity in naïve LN. This is in line with COX2 ∆CCL19Cre mice completely lacking ptgs2 mRNA expression in T zone FRC ( Fig. 5A ). Ablation of Cox2 expression did neither alter ptgs1 transcript levels nor affect ccl19 expression in these cells (data not shown). Given that COX2/PGE 2 expression is constitutive in LN FRC, we analyzed the hematopoietic and non-hematopoietic cell types in spleen and pLN of naïve COX2 ∆CCL19cre mice using flow cytometry and histology, however, no major difference was observed in the size and organization of lymphocyte and FRC populations ( in LN and spleen of d8 infected COX2 ∆CCL19cre mice showed a higher surface expression of PD-1 ( Fig. 5F and Supplementary Fig. 5F ), which is a negative regulator of T cell activation in chronic T cell responses to persisting infections or tumors (25, 26). Similar findings have been reported recently for LCMV-specific CD8+ T cell responses in mPges1-or EP2/4-deficient mice (18) suggesting that this effect is most probably PGE 2 driven. To assess effector function of LCMV specific CD8+ T cells in these two mouse models on d8 p.i., we determined their cytokine production as well as the viral clearance by measuring the virus titer in the blood. Indeed, CD8+ T cells isolated from COX2 ∆CCL19cre mice exhibited a slightly reduced IFNg and TNFa production upon re-stimulation with different LCMV peptides ( Supplementary   Fig. 5G ), suggesting COX2 in FRC has weak proinflammatory effects on the early phase of the T cell response. However, the viral burden in the blood was similar in both groups (Fig.   5G ). In line with previous studies (27, 28), our histological analysis showed a dramatic impact of LCMV infection on the LN compartmentalization as well as the function of LN stroma cells as CCL21 source ( Supplementary Fig. 5H ) which was comparable between COX2 ∆CCL19cre and control mice. This defect was transient in both mouse models as the lymph node organization and CCL21 expression was restored by day 21 post infection ( Fig. 6A ).
FRC-specific deletion of COX2 leads to a stronger T cell response in the chronic phase of LCMV infection and a better virus control
Given the higher T cell responses previously observed in mPges1 -/mice (18) , we wished to assess whether COX2 expression in FRC was responsible for suppressing chronic T cell responses. First, we confirmed that LN FRC are the principal cell type displaying Cre-activity on d19 p.i. with clone 13 virus ( Supplementary Fig. 6A and data not shown), similar to naive mice. On d21 post infection, we detected a significant increase in number of total and LCMVspecific CD8+ T cells in pLN and to a lesser extent in the spleen of COX2 ∆CCL19cre relative to wt mice, especially for np396-specificities ( Fig. 6B , Supplementary Fig. 6B ). While the LCMVspecific cells isolated from COX2 ∆CCL19cre mice showed a similar PD-1 and IFNg expression level as control mice, the TNFa expression level was increased in cells isolated from pLN ( Fig. 6C and D) but not the spleen ( Supplementary Fig. 6C ). Given the strong increase in gp33-and np396-specific T cells in LN of d21, the total number of IFNg+ and TNFa+ T cells is increased by more than 100% in COX2 ∆CCL19cre mice (Fig. 6E ). This increased CTL response translated into a significant improvement in viral clearance in the blood and LN of COX2 deficient animals ( Fig. 6F and data not shown). Together these findings demonstrate that COX2 activity within LN FRC has an important role in suppressing chronic T cell responses during persisting viral infections, by downregulating CTL numbers and function and consequent reduction of viral clearance.
Discussion
In the current study, we show that FRC display a highly active COX2/PGE 2 pathway that dampens the expansion of in vitro activated CD8 and CD4 T cells by acting via EP2/4
receptors. This pathway dampens both weak and strong T cell responses, in contrast to FRCderived NO which is produced mainly during strong TCR stimulations pointing to two distinct inhibitory pathways in FRC. Using mice selectively lacking COX2 in lymphoid tissue FRC we provide direct evidence for an in vivo function of FRC in downregulating T cell responses, not during the early phase of an acute CD8 T cell response but later during a chronic response.
Thus, pLN FRC and COX2 expressed by them can have anti-inflammatory roles on T cell responses in vivo.
FRC have been proposed to play a dual role for adaptive immunity, either promoting or inhibiting it (1, 2), similar to myeloid and T cells. In vitro experiments have revealed that FRC can act as bystander cells to dampen T cell responses, independently of effects on regulatory T cells or APC, by sensing IFNg and TNFa released early during T cell priming and leading to FRC-derived NO release (9-11). This latter concept is consistent with in vivo evidence of an exaggerated T cell response to immunogenic stimuli in iNOS-deficient mice (9-11). We now extend these findings by showing that iNOS expression and NO release by FRC in vitro is mainly observed during strong T cell responses characterized by a marked early IFNg secretion, but not in weaker T cell responses where IFNg levels are low. Due to the lack of iNOS fl/fl or suitable chimeric mice (9, 11) this concept could only be tested using iNOS -/mice where myeloid cells are also iNOS-deficient. Consistent with our in vitro findings, we show here that primary T cell responses were enhanced in iNOS -/mice only in response to a high but not low antigenic stimulation. More striking is the enhancement we observed for the secondary T cell expansion to a low antigen dose in iNOS -/mice, similar to an earlier report (23) and consistent with an expected enhancement of the early IFNg expression by restimulated memory T cells (22) . Therefore, this regulatory pathway via NO release may only come into effect in acute type I immune responses which have the potential to damage We tested the importance of the COX2 pathway specifically in FRC, both in vitro and in vivo.
We observed that COX2 is expressed constitutively in FRC of naïve LN at levels clearly above those observed for COX1, consistent with a recent report (31). This is opposite of the usual COX expression pattern, with COX1 being typically constitutively expressed and COX2 being induced during inflammation (12, 16) . LN FRC maintain this property even in vitro,
including after several weeks of culture, suggesting this is an intrinsic and imprinted feature in murine FRC (11, 31 ). This expression is not much altered upon stimulation by cytokines or TLR2/4 ligands (11) , in contrast to most other cell types, including myeloid cells, that depend upon these signals for COX2 expression (16) . Of note, the gut lamina propria is one of the rare tissues displaying high COX2 expression and thereby an immune microenvironment that attenuates T cell immunity to the diverse commensals and food antigens. Interestingly, adherent stromal cells were identified as major source of COX2, displaying constitutive PGE 2 expression without need for exogenous stimuli (35, 36) . A recent study revealed that also human FRC are capable to suppress T cell proliferation and differentiation in a COXdependent manner (34). In contrast to murine FRC, both COX1 and COX2 appear to be constitutively expressed in human FRC (31, 34).
COX enzymes are the rate-limiting enzymes for the generation of five different prostanoids, including PGE 2 . We decided to focus on this lipid mediator, as it is a known negative regulator of T cell responses, and as its high constitutive expression in LN FRC came as a surprise to us given that LN are sites of adaptive immune response induction. Remarkably, the expression in FRC was 50-fold above LN macrophages for COX2 transcripts and 10-fold for PGE 2 suggesting FRC may be poised to dampen T cell responses. Indeed, ex vivo FRC inhibited CD4 and CD8 T cell activation and expansion in a COX2-dependent manner, and to an extent similar to purified PGE 2 (31). In addition, blocking of the two major PGE 2 -receptors on T cells, EP2 and EP4, mimicked this effect, providing strong evidence for PGE 2 being the principal COX2-dependent prostanoid responsible for attenuating T cell responses in cocultures with pLN FRC.
Given the high expression of COX2 and PGE 2 in pLN FRC before the start of T cell priming, we hypothesized this pathway could ensure that responses by non-specific or weakly activated T cells are avoided (2) . When we varied either the antigen affinity or quantity in the co-culture assay, FRC-mediated suppression abolished responses to weaker stimuli, while stronger stimuli overcame these inhibitory effects despite the combined presence of COX2and iNOS-dependent factors. Importantly, inhibition of COX2 or EP2/4 but not iNOS allowed again the expansion of weakly responding T cells in FRC containing cultures. Several findings support the notion that less T cells got recruited into the response: we observed 1) more undivided cells; 2) a reduced CFSE dilution of those cells that did divide; 3) diminished expression of activation markers on undivided but not proliferating T cells; 4) strongly reduced numbers of antigen-specific T cells generated; 5) fewer effector cells capable of expressing IFNg while killing of targets occurred normally. These observations are consistent with earlier reports on PGE 2 effects on T cells, both by interfering with TCR signaling as well as by deviating in some settings from an IFNg-driven response (12) (13) (14) . For example, when human CD4+ T cells were activated by suboptimal anti-CD3/CD28 stimulation in vitro, most transcriptional changes were ablated by a simultaneous PGE 2 exposure, leading to strongly reduced cell cycle entry while not altering proapoptotic pathways (20) . Lck, zap70 and Ca-flux have been identified as the main targets of negative regulation by PGE 2 in T cells, with the suppression being surmountable by a stronger stimulation (20) . These findings were recently confirmed in the context of murine T cells cocultured with either murine or human LN FRC ); however, this difference was lost 24h later (31). Currently, the reason for this discrepancy is unclear but could be based on differences in timing or antigen dose reaching the LN. It seems also plausible that COX2dependent processes in non-FRC may have contributed to the phenotype described by Cui and colleagues as activated macrophages or DC were also deficient in prostanoid synthesis in their mouse model (31). Of note, they observed only a delay of the response and not a qualitative or quantitative difference at time points later than 48h. Nevertheless, these data indicate that PGE 2 present within the LN may modulate in some settings the T cell priming or early expansion phase, and possibly clonal selection and amplification.
Given the normal T cell expansion we observed in the early phase of the response to LCMV we focused our attention on the chronic phase where mice deficient in EP2/4-expression in activated T cells or globally deficient in mPges-1 have previously been shown to have an enhanced antiviral CD8+ T cell response on d21 post LCMV infection, both in number, effector function and reduction of the 'exhaustion' phenotype (18) . That study demonstrated that PGE 2 acts on virus-specific CD8+ T cells via EP2/4 and restricts their survival but not their proliferation, presumably without Treg involvement. Interestingly, EP2/4 expression is increased in PD-1 hi T cells on d21, and inhibiting both COX2 and PD-L1 showed additive effects on T cell responsiveness (18) . However, this report did not reveal which cells were the main targets of COX2 inhibition. Interestingly, we observed that COX2 ∆CCL19cre mice reproduced the findings of Kaech and colleagues, notably the increased numbers of endogenous virus-specific CD8+ T cells of three different specificities, along with their effector function leading to a better virus control without evidence for increased immunopathology (18) . Therefore, we propose that FRC within T zones of SLO, like LN and spleen, negatively regulate the survival of chronically activated CD8+ T cells via their constitutive production of PGE 2 , presumably by enhancing the chronic TCR signals that drive T cell exhaustion.
Importantly, COX2 inhibition in FRC can partially reverse this effect.
COX inhibitors are the most frequently used drugs to prevent inflammation. Therefore, our results suggesting COX2/PGE 2 -expressing FRC lead to an inhibition rather than enhancement of T cell responses may seem paradoxical. However, COX-dependent prostanoids and PGE 2 in particular are well known for their dual role in inflammation and immunity (12) (13) (14) (15) . PGE 2 has been observed to be anti-inflammatory not only in persisting viral infections (18) , but also in other chronic diseases, such as various tumor types, where COX2 and/or PGE 2 expression by tumors or myeloid derived suppressor cells have been correlated with suppression and deviation of anti-tumor T cell responses, as well as with worse disease outcome (19, 41) . Currently there are great needs for drugs that can complement the existing checkpoint inhibitors in order to improve the proportion of patients showing clinical benefit.
Interestingly, combined inhibition of PD-L1 and COX2 showed additive effects for the recovery of CD8+ T cell immunity in both models of chronic infection and tumors, with apparently limited side effects (18, 19) suggesting COX inhibitors may be used in combination therapy. More specific drugs targeting either PGES, PGE 2 or EP2/4 could be of even greater benefit as they do not affect the other four COX-dependent prostanoid pathways (42). While inhibition of the COX or PGE 2 pathway may act on cells residing within the site of chronic inflammation, including tumor cells and cancer associated fibroblasts (43) our study indicates that such inhibitors will also interfere with the anti-inflammatory capacity of FRC inside SLO, presumably within T zones, and may permit an improvement of the cancer-immunity cycle (44), namely a revitalization of previously exhausted T cell clones that can then seed again the sites of inflammation or cancer and maintain an effective immune response.
In summary, we propose that LN FRC act as a rheostat restraining T cell responses in at least two different ways, with weak responses being prevented by the omnipresent PGE 2 and stronger responses being dampened by both PGE 2 
Stromal and hematopoietic cell isolation
In order to investigate lymph node stromal cells, tissues were collected and digested as described elsewhere (3 
Cell lines
The wt FRC cell line pLN2 was described previously (11) and stems from naïve pLN of B6 mice. iNOS -/-FRC cell lines were generated accordingly from pLN of iNOS -/mice. All cell lines were cultured in RPMI complete medium (RPMI 1640, 10%FCS, 10mM HEPES, 50µM
b-Mercaptoethanol, P/S). For experiments cells were used between passages (p) 24-32 (pLN2) and p23-27 (iNOS -/-FRC), respectively.
In vitro T cell activation assay using agonistic antibodies
To investigate the effect of FRC on T cell activation co/cultures of cells were performed as described previously (11) . Briefly, pLN2 or NOS2 -/-FRC lines were plated at 2.500 cells per populations of lymph nodes were identified as previously described (3). For RNA isolation cells were directly sorted into lysis buffer (RNeasy micro kit, Qiagen).
Re-stimulation and in vitro cytotoxicity assay
Lymphocytes from spleen or pLN of LCMV infected animals were isolated and 2 x10 6 cells were seeded per 96-well. Cells were stimulated in vitro with 1µM of gp33 (KAVYNFATC) or np396 (FQPQNGQFI) peptide (ECM Microcollections) for 30 minutes at 37°C before BrefeldinA (10µg/ml, AppliChem) was added. After another 4h of incubation at 37° cells were harvested, washed and stained for surface or intracellular epitopes followed by analysis using flow cytometry. In vitro cytotoxicity assays were performed as previously described (11) .
Histology
Tissues of infected animals were fixed with 2% PFA for at least 4h, followed by overnight incubation in 30% sucrose before embedding in O.C.T. (Sakura Finetek). 8µm cryosections were generated and immunofluorescence staining performed as described recently (3 
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Statistical analysis
Statistical analyses were performed with Prism (version 6.0b and 7.0d, GraphPad Software).
Unpaired t-test (normally distributed data) or Mann-Whitney test (for not normally distributed
data) were used to compare two data sets. To compare multiple groups, One-Way Kruskal- 
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